DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies

VEGF-targeted therapy increases both the progression-free (PFS) and overall survival (OS) of patients with metastasized renal cell cancer (mRCC). Identification of molecular phenotypes of RCC could improve risk-stratification and the prediction of the clinical disease course. We investigated whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Inga, Dubrowinskaja, Natalia, Abbas, Mahmoud, Seidel, Christoph, Kogosov, Michael, Scherer, Ralph, Gebauer, Kai, Merseburger, Axel S., Kuczyk, Markus A., Grünwald, Viktor, Serth, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954691/
https://www.ncbi.nlm.nih.gov/pubmed/24633192
http://dx.doi.org/10.1371/journal.pone.0091440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954691/
https://www.ncbi.nlm.nih.gov/pubmed/24633192
http://dx.doi.org/10.1371/journal.pone.0091440

Ejemplares similares